3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
7
Terminated
2
Recruiting
2
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Small Cell Lung Carcinoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Interventions
pembrolizumab
241
Carboplatin
166
Injections
138
Paclitaxel
118
Gemcitabine
116
Bevacizumab
113
Cisplatin
105
Docetaxel
80
Cyclophosphamide
77
Pemetrexed
76
Capecitabine
69
Fluorouracil
67
Oxaliplatin
65
Fulvestrant
58
Nivolumab
55
fludarabine
54
Cetuximab
52
Leucovorin
51
130-nm albumin-bound paclitaxel
48
Dexamethasone
46
Rituximab
41
atezolizumab
37
venetoclax
35
Drug Therapy
35
toripalimab
34
enzalutamide
34
Irinotecan
33
durvalumab
32
Prednisone
32
Letrozole
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
amrubicin
×
Clear all
NCT06203210
2026-06-02
IDeate-Lung02
Daiichi Sankyo
Phase 3
Recruiting
540 enrolled
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled